In a recent video, “RedChip Money Report,” President and CEO of RedChip Dave Gentry interviews Dr. Robin Smith, chairman and CEO of NeoStem.
NeoStem is a biopharmaceutical company that is developing and manufacturing stem cell therapies in order to capitalize on the current paradigm shift. It is a New York Stock Exchange company that was ranked No. 7 nationally in Deloitte’s 2012 Technology Fast 500. Smith has been the CEO of NeoStem for at least six years.
In the video, she says that the company creates “novel cell therapy products to treat chronic diseases.” It also has a contract manufacturing business that helps other countries to develop their cell therapy products. Smith says that stem cell treatments started with bone marrow transplants, and that many blood disorders and cancer treatments incorporate cell therapy. Cell therapy focuses more on the causes of disease in order to prolong the quality of life.
She explains:
“We realized these cells of our body are a way to naturally repair itself. And we realized that we can take these cells from the different parts of our body and create therapies or vaccines to help treat differnet patients with chronic diseases.”
NeoStem received grants from the National Institute of Health and the Department of Defense. Smith says that in addition to cardiovascular therapy, the company is developing therapies in autoimmune disorders and regenerative medicine.
She says:
“Our Vsels, these very small embryonic-like stem cells, we believe have regenerative properties. Using the Department of Defense funding and through different grants, we’re looking to developing therapies for things like wounds—closing wounds more quickly; bones—through osteoporosis or through damage; vision—through retinal disease or macro degeneration. It’s a way to restore damaged tissue.”
Smith states that the Department of Defense is very focused on helping companies with exciting technologies, to develop them and get them into the clinic. This is so cell therapies that are safe, cost effective, and can treat damaged tissue and underlying disease to get into clinics as soon as possible.
RedChip is an international small-cap research firm and an Inc. 5000 company. "The RedChip Money Report" airs on Saturdays at 2:30 p.m. on Fox Business News and discusses small-cap investing, interviews with Wall Street analysts and executives of public companies, and provides financial book reviews. Dave Gentry is a leading authority on small-cap stocks, has been a consultant to hundreds of public companies, and has made multiple guest appearances on both CNBC and Fox Business News.